Abstract

Background: Recent advances in immunotherapy for head and neck squamous cell carcinoma (HNSCC) have led to implementation of anti-programmed death receptor 1 (PD-1) immunotherapy to standard of care for recurrent/metastatic HNSCC. However, the majority of tumors do not respond to these therapies, indicating that these tumors are not immunogenic or other immunosuppressive mechanisms might be at play.Aim: Given their role in carcinogenesis as well as in immune modulation, we discuss the relation between the STAT3, PI3K/AKT/mTOR and Wnt signaling pathways to identify potential targets to empower the immune response against HNSCC.Results: We focused on three pathways. First, STAT3 is often overactivated in HNSCC and induces the secretion of immunosuppressive cytokines, thereby promoting recruitment of immune suppressive regulatory T cells and myeloid-derived suppressor cells to the tumor microenvironment (TME) while hampering the development of dendritic cells. Second, PI3K/AKT/mTOR mutational activation results in increased tumor proliferation but could also be important in HNSCC immune evasion due to the downregulation of components in the antigen-processing machinery. Third, canonical Wnt signaling is overactivated in >20% of HNSCC and could be an interesting pleotropic target since it is related to increased tumor cell proliferation and the development of an immunosuppressive HNSCC TME.Conclusion: The molecular pathology of HNSCC is complex and heterogeneous, varying between sites and disease etiology (i.e., HPV). The in HNSCC widely affected signaling pathways STAT3, PI3K/AKT/mTOR and Wnt are implicated in some of the very mechanisms underlying immune evasion of HNSCC, thereby representing promising targets to possibly facilitate immunotherapy response.

Highlights

  • In 2018, 700,000 patients were diagnosed with head and neck squamous cell carcinoma (HNSCC) worldwide, and 350,000 patients died of the disease [1]

  • STAT3 and the Phosphatidylinositol 3-kinases (PI3Ks)/AKT/mTOR- and Wntpathways are of particular interest, because they are implicated in some of the very mechanisms believed to be responsible for primary or acquired resistance to immune checkpoint inhibitors (ICIs) therapy

  • The milieu of cytokines and other mediators including IFNγ and vascular endothelial growth factor (VEGF) seems tailorable through the proposed pathways, as well as the expression of MHCI/II and immune checkpoints like programmed death receptor 1 (PD-1)/L1 and cytotoxic Tlymphocyte–associated antigen 4 (CTLA-4)

Read more

Summary

Introduction

In 2018, 700,000 patients were diagnosed with head and neck squamous cell carcinoma (HNSCC) worldwide, and 350,000 patients died of the disease [1]. Besides mutational changes in oncogenes and most tumor suppressor genes, epigenetic changes and chromosomal instability add to the overall molecular heterogeneity [3, 4]. This variable genetic background translates into a variety of tumor characteristics, challenges treatment efficacy and demands personalized approaches. Heterogeneity is observed in the immune composition of the tumor microenvironment (TME) of HNSCC, depending on etiology and/or localization of the tumor as recently reviewed by us and others [5,6,7]. Recent advances in immunotherapy for head and neck squamous cell carcinoma (HNSCC) have led to implementation of anti-programmed death receptor 1 (PD-1) immunotherapy to standard of care for recurrent/metastatic HNSCC. The majority of tumors do not respond to these therapies, indicating that these tumors are not immunogenic or other immunosuppressive mechanisms might be at play

Objectives
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call